Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Vimta Labs

VIMTALABS
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Vimta Labs Share price and Fundamental Analysis

View All Details
View All Details
Vimta Labs Ltd., established in 1984, is India's most comprehensive contract research and testing organization, providing wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device and many other industries. Broadly, these services include: Drug discovery, development and drug life cycle management support services in the areas of preclinical research (GLP and non-GLP), clinical research, central lab, and cGMP as well as non-GMP analytical services for pharmaceutical and biopharmaceutical companies; Preclinical research and testing services for medical device companies; Contract research and testing for Agro-science companies; Food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, regulators; Clinical diagnostics services to patients, clinicians, hospitals and Environmental regulatory services such as impact assessments and post project monitoring, to industries such as infrastructure, power, cement, oil & gas, mining etc.
Company Incorporation1990
ChairmanS P Vasireddi
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
2,239.08
PE Ratio
33.26
Industry P/E
41.54
PEG Ratio
0.47
ROE
17.78%
ROCE
23.13%
ROA
14.16%
Total Debt (Cr)
8.51
Debt to Equity
0.02
Dividend Yield
0.2%
EPS
30.25
Book Value & P/B
170.25 x 5.91
Face Value
2
Outstanding Shares(Cr)
2.23
Current Ratio
3.18
EV to Sales
6.5

Included In

+More

Stock Returns

1 Week+5.59%
1 Month-1.27%
6 Months+4.97%
1 Year+99.71%
3 Years+218.64%
5 Years+1048.23%

CAGR

1 Year CAGR

Revenue Growth

+0.02%

Net Profit Growth

-14.87%

Operating Profit Growth

-7.68%

Dividend Growth

0%

Stock Returns CAGR

+102.17%
no_data

No Stocks

Smart Score

2.4
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Mar 25

Promoters : 36.70%

FIIs : 3.66%

DIIs : 1.43%

Public : 58.20%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
DII Shareholding Increased by 0.28% to 1.43% in March 2025 Qtr
Promoter Shareholding Decreased by 0.06% to 36.7% in March 2025 Qtr
FII Shareholding Decreased by 0.15% to 3.66% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Vimta Labs Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Vimta Labs Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Vimta Labs Ltd., established in 1984, is India's most comprehensive contract research and testing organization, providing wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device and many other industries. Broadly, these services include: Drug discovery, development and drug life cycle management support services in the areas of preclinical research (GLP and non-GLP), clinical research, central lab, and cGMP as well as non-GMP analytical services for pharmaceutical and biopharmaceutical companies; Preclinical research and testing services for medical device companies; Contract research and testing for Agro-science companies; Food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, regulators; Clinical diagnostics services to patients, clinicians, hospitals and Environmental regulatory services such as impact assessments and post project monitoring, to industries such as infrastructure, power, cement, oil & gas, mining etc.

The Company was awarded ISO 9002 Certification under ISO/IEC Guide-25 as Certified Competent Laboratory and Quality Endorsed Company by Standards Australia Quality Assurance Services Pty. Ltd in 1994.

In 1997, the Company entered into a Joint Venture with Russian Centre for Testing and Certification, ROSTEST Moscow with an investment of 24% of the total Paidup Captial. The main essence of this Joint Venture was to diversify the activities in to preshipment inspection services for all Indian exports to Russia.

During 2002, the company begun to offer Clinical Diagnostics Services. Clinical Specialty Diagnostics has been an internal requirement to screen the clinical trial subjects. Facilities were created in the year 2000 to speed up the clinical trials.

The Company is now expanding its operations by five times of its existing capacities at S P Biotech Park, Genome Valley, Turkapally Village, Shamirpet Mandal, Ranga Reddy Dist. The project is expected to commence from September 2005.

During the year 2006-07, the Analytical and Clinical Reference Lab facilities was shifted from the existing Cherlapally Facility to the newly established Life Sciences Facility in S.P.Biotech Park, Genome Valley, Hyderabad which started commercial operations from September, 2006.

During the year 2020 Company acquired 100% Equity Shares of Emtac Laboratories Private Limited, on 04th March 2020, making Emtac a wholly owned subsidiary of the Company.

Vimta Labs Share Price

Vimta Labs share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Vimta Labs Market Cap

Market capitalization of Vimta Labs indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Vimta Labs is valued compared to its competitors.

Vimta Labs PE Ratio

Vimta Labs PE ratio helps investors understand what is the market value of each stock compared to Vimta Labs 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Vimta Labs PEG Ratio

The PEG ratio of Vimta Labs evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Vimta Labs ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Vimta Labs generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Vimta Labs ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Vimta Labs in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Vimta Labs Total Debt

Total debt of Vimta Labs shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Vimta Labs Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Vimta Labs compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Vimta Labs CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Vimta Labs over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Vimta Labs Technical Analysis

Technical analysis of Vimta Labs helps investors get an insight into when they can enter or exit the stock. Key components of Vimta Labs Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Vimta Labs shares often struggle to rise above due to selling pressure.

Vimta Labs Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Vimta Labs ’s financial health and profitability.

Vimta Labs Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Vimta Labs Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Vimta Labs Financials

The financials of Vimta Labs provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Vimta Labs Profit and Loss Statements

The profit and loss statement of Vimta Labs highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Vimta Labs .

Vimta Labs Balance Sheet

The balance sheet presents a snapshot of Vimta Labs ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Vimta Labs Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App